Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin

Moore A.; Hurley K.; Moore S.A.

Publication

Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin

Moore A.; Hurley K.; Moore S.A.

Publisher

Elsevier

Date

2022

Abstract

Actinic keratoses are precancerous lesions that may progress to invasive squamous cell carcinoma (SCC) in 0.1% to 20%. Current treatment options are limited by poor cosmetic outcomes, intolerable side effects, or poor patient compliance. Tirbanibulin 1% ointment is a synthetic antiproliferative agent approved by the Food and Drug Administration in 2020 for the treatment of actinic keratoses in a contiguous area of 25 cm2 as a once-daily topical treatment for 5 days. We recently reported the case of a periungual SCC that resolved with once-daily tirbanibulin 1% ointment application for 5 consecutive days. The lesion resolved on day 5 of application, with no perceived recurrence at 1 year.